For the Inventor, By the Inventor

Enter assignee name

Lausanne, Switzerland

Amazentis Sa

USPTO Granted Patents = 37

CIPO Patents = 4

EPO Patents = 13

Trademarks = 17

Forward Citations = 162

Loading Chart...

Loading Chart...

27 inventors (with patents filed for the assignee):

Christopher Rinsch (34 out of 47 patents)

Penelope Andreux (26 out of 30 patents)

William Blanco-Bose (23 out of 23 patents)

4. Johan Auwerx (13 out of 19 patents)

5. Bernard Schneider (13 out of 17 patents)

6. Laurent Mouchiroud (13 out of 15 patents)

7. Carmen Sandi (9 out of 10 patents)

8. Eija Pirinen (9 out of 9 patents)

9. David Genoux (9 out of 9 patents)

10. Charles Thomas (6 out of 6 patents)

11. Richardus Houtkooper (6 out of 7 patents)

12. Wolfgang Skranc (5 out of 16 patents)

13. Dongryeol Ryu (4 out of 5 patents)

14. Anurag Singh (4 out of 6 patents)

15. Rune A Ringom (3 out of 3 patents)

37 patents: Sort by Forward Citations

1. 12338224 - Process-scale synthesis of urolithin A (2025-06-24),

2. 12310943 - Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders (2025-05-27),

3. 12297182 - Compositions comprising an urolithin compound (2025-05-13),

4. 12220424 - Compositions comprising nicotinamide riboside and a urolithin (2025-02-11),

5. 12109190 - Urolithins as immune response enhancers (2024-10-08),

6. 12036205 - Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders (2024-07-16),

7. 12030863 - Prodrugs of urolithins and uses thereof (2024-07-09),

8. 11969408 - Method for improving mitophagy in subjects (2024-04-30),

9. 11931336 - Enhancing autophagy or increasing longevity by administration of urolithins (2024-03-19),

10. 11931335 - Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof (2024-03-19),

11. 11925616 - Compositions comprising urolithin compounds (2024-03-12),

12. 11903922 - Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders (2024-02-20),

13. 11878964 - Compositions comprising an urolithin compound (2024-01-23),

14. 11634401 - Process-scale synthesis of urolithin A (2023-04-25),

15. 11426380 - Urolithins as immune response enhancers (2022-08-30),

Amazentis SA is a Swiss biotechnology company specialized in the development of innovative, science-backed products for improving human health spanning cellular health/aging, metabolism, and muscle function. Their mission is to harness scientific advancements to promote healthy aging and improve overall wellbeing. With a focus on pioneering research, cutting-edge technology, and rigorous clinical trials, Amazentis aims to deliver groundbreaking interventions for human health and longevity.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

37 Patents

#11 in Lausanne

#362 in Switzerland

#17,710 in the World

Lausanne, Switzerland

Amazentis Sa

Forward Citations = 162

27 inventors:

Christopher Rinsch (34 out of 47 patents)

Penelope Andreux (26 out of 30 patents)

William Blanco-Bose (23 out of 23 patents)

4. Johan Auwerx (13 out of 19 patents)

5. Bernard Schneider (13 out of 17 patents)

Please report any incorrect information to support@idiyas.com

Loading…